Exelixis
EXEL
#2109
Rank
A$11.30 B
Marketcap
$39.63
Share price
-1.53%
Change (1 day)
18.25%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of June 2024 : A$0.29 B

According to Exelixis's latest financial reports the company's total debt is A$0.29 B. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31A$0.27 B-0.24%
2022-12-31A$0.27 B296.31%
2021-12-31A$70.51 M10.7%
2020-12-31A$63.7 M-6.73%
2019-12-31A$68.29 M222.68%
2018-12-31A$21.16 M10.62%
2017-12-31A$19.13 M-92.71%
2016-12-31A$0.26 B-54.27%
2015-12-31A$0.57 B31.8%
2014-12-31A$0.43 B11.82%
2013-12-31A$0.38 B20.22%
2012-12-31A$0.32 B82.92%
2011-12-31A$0.17 B-14.02%
2010-12-31A$0.20 B131.29%
2009-12-31A$89.01 M-47.76%
2008-12-31A$0.17 B22.53%
2007-12-31A$0.13 B-9.89%
2006-12-31A$0.15 B-24.14%
2005-12-31A$0.20 B6.83%
2004-12-31A$0.19 B27.42%
2003-12-31A$0.14 B13.88%
2002-12-31A$0.13 B36.84%
2001-12-31A$95.9 M258.66%
2000-12-31A$26.73 M32.11%
1999-12-31A$20.23 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
A$32.15 B 10,725.89%๐Ÿ‡ฌ๐Ÿ‡ง UK
A$38.18 B 12,757.84%๐Ÿ‡ซ๐Ÿ‡ท France
A$56.67 B 18,983.21%๐Ÿ‡บ๐Ÿ‡ธ USA
A$80.99 B 27,172.41%๐Ÿ‡บ๐Ÿ‡ธ USA
A$93.95 B 31,536.17%๐Ÿ‡บ๐Ÿ‡ธ USA
A$62.23 B 20,853.25%๐Ÿ‡บ๐Ÿ‡ธ USA
A$103.00 B 34,582.38%๐Ÿ‡บ๐Ÿ‡ธ USA
A$5.33 M-98.20%๐Ÿ‡บ๐Ÿ‡ธ USA
A$58.01 M-80.47%๐Ÿ‡บ๐Ÿ‡ธ USA